Showing results (21-30 of 57) with videos related to
Sort By:
Pageof 6
The British Journal of Dermatology|May 25, 2023
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, et al.JAMA Dermatology|July 6, 2022
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With PsoriasisZenas Z N Yiu, Gabrielle Becher, Brian Kirby, et al.The British Journal of Dermatology|April 4, 2023
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)Duc Binh Phan, Anthony P Bewley, Catherine H Smith, et al.The British Journal of Dermatology|May 4, 2026
Serious infection risk with systemic treatments for psoriasis: A cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)Heber Rew Bright Bright, Catherine H Smith, Philip Laws, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 18, 2026
Prognostic prediction models for psoriatic arthritis in psoriasis: A systematic reviewFatimah Khoda, Yasmin Khan, William W Y Haw, et al.The British Journal of Dermatology|December 5, 2023
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)Oras A Alabas, Kayleigh J Mason, Zenas Z N Yiu, et al.JAMA Dermatology|December 2, 2020
Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators RegisterZenas Z N Yiu, Kayleigh J Mason, Philip J Hampton, et al.JAMA Dermatology|March 5, 2025
Effectiveness of Adalimumab Biosimilars and Originator for PsoriasisDuc Binh Phan, Anthony P Bewley, Philip Laws, et al.BMJ Open|August 31, 2018
Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysisAaron Mark Drucker, Alexandra Ellis, Zarif Jabbar-Lopez, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 29, 2025
Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort studyLeila Motedayen Aval, Zenas Z N Yiu, Oras A Alabas, et al.Pageof 6